Ambrx Biopharma Inc ADR (AMAM)

NYSE
15.60
-1.11(-6.64%)
After Hours
16.00
-0.18(-1.11%)
- Real-time Data
  • Volume:
    27,387
  • Bid/Ask:
    15.25/16.75
  • Day's Range:
    15.10 - 16.86

AMAM Overview

Prev. Close
16.71
Day's Range
15.1-16.86
Revenue
-
Open
16.86
52 wk Range
14.94-22.87
EPS
-
Volume
27,387
Market Cap
587.64M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
57,686
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
37,669,455
Next Earnings Date
Dec 01, 2021
What is your sentiment on Ambrx Biopharma Inc ADR?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellNeutral
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellBuy

Ambrx Biopharma Inc ADR Company Profile

Ambrx Biopharma Inc ADR Company Profile

Sector
Services
Employees
70

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.